AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06670261 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Retrospective pseudo-anonymized clinical and scannographic data from the routine management of patients in rhino-sinusology consultations.
Study NCT06673290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus (RAPAMUNE)
Description: Use of different doses of the same drug
Study NCT06673290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (RAPAMUNE)
Description: Use of different doses of the same drug
Study NCT06672068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin
Description: TY-9591 80mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
Study NCT06672068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin
Description: TY-9591 160mg QD+pemetrexed 500mg/m²（D1，Q3w）+Carboplatin AUC5/ Cisplatin 75mg/m²（D1，Q3w\*4 cycles）
Study NCT06672471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Post Operative Antibiotics for intervention group
Description: No Post Operative Antibiotics in patients going clean contaminated head and neck surgery
Study NCT06672471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Operative Antibiotics for one day
Description: Control group will receive perioperative as well as post operative antibiotics for one day
Study NCT06670846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lollipop
Description: Distraction using a Lollipop 15 minutes before anesthesia
Study NCT06670846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: distraction using intranasal Midazolam
Description: Distraction using intranasal Midazolam 15 minutes before anesthesia
Study NCT05257603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RPCW
Description: Psychosocial intervention that includes two in-person group sessions two weeks apart and two on-line units during the intervening two weeks. Behavioral training, educational materials, discussions and videos, as well as interactive online materials are included to increase awareness of sexual assault cues, dating and drinking protective behavioral strategies, barriers to defending oneself, and saying no to hazardous drinking and sexual advances.
Study NCT05257603 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HEC
Description: Health Education time and attention control that includes two in-person sessions two weeks apart and two on-line units during the intervening two weeks. The in-person sessions cover stress management and sleep, while the online units cover nutrition and physical activity. The in-person and online sessions are designed to foster discussion and be interactive.
Study NCT06672991 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy
Description: Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patients underwent endoscopic procedures using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis, 7 to 15 days after ERCP in a single hospitalization
Study NCT06672991 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancreatography;laparoscopic cholecystectomy
Description: Initially, ERCP with EST was performed by an endoscopist with the consent of the patient or legal representative. The patient underwent the endoscopic procedure using fluoroscopy in the operating room, under general anesthesia. Subsequently, laparoscopic cholecystectomy was performed on a delayed basis for readmission, 1 month after ERCP under general anesthesia.
Study NCT06671379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009 monotherapy
Description: SHR-A2009 monotherapy ，SHR-A2009 will be administered intravenously
Study NCT06671379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platinum-based dual-agent chemotherapy
Description: Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously
Study NCT06588634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlowTriever System
Description: Mechanical thrombectomy for pulmonary embolism
Study NCT06588634 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care treatment for pulmonary embolism
Study NCT06296979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phrenic nerve neuromodulation
Description: The intervention group will receive the usual physiotherapy treatment at the health center and will also receive neuromodulation on the phrenic nerve at its exit through the anterior cervical region. The neuromodulation technique will be applied for 10 minutes.
Study NCT06296979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: common Physical therapy
Description: the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
Study NCT06296979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: common Physical therapy
Description: the usual treatment of the center consisting of manual therapy, exercise and thermotherapy will be performed.
Study NCT05744895 — intervention group
Intervention type: DEVICE
Intervention: Device: Robotic MAKO total knee
Description: Prospective TKA patient receiving total knee arthroplasty using the MAKO robotic machine
Study NCT05744895 — intervention group
Intervention type: DEVICE
Intervention: FocusMotion knee brace
Description: Focusmotion knee brace measures range of motion during exercises
Study NCT05744895 — intervention group
Intervention type: DEVICE
Intervention: Fitbit tracking device
Description: Fitbit will measure patients steps, HR, and sleep
Study NCT05744895 — intervention group
Intervention type: DEVICE
Intervention: FocusMotion app
Description: Will survey patients with PROMS
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: an anti-HER2 antibody-drug conjugate (ADC)
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: an anti-programmed death ligand 1 (PD-L1) antibody
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: an anti-programmed death-1 (PD1) antibody
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: Trophoblast cell-surface antigen 2 (TROP2) ADC
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: goserelin
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: letrozole
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Albumin paclitaxel
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Albumin paclitaxel
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin
Study NCT06368479 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStatis HBsAg Test
Description: Capillary (fingerstick) blood, EDTA venous whole blood, serum and plasma samples to be tested on the iStatis HBsAg Test at the point of care setting.
Study NCT05683795 — intervention group
Intervention type: OTHER
Intervention: Consensus study
Description: Modified-Delphi study and consensus meetings
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT05434195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arcofolin® 5-Methyltetrahydrofolate
Description: 5-methyltetrahydrofolate (5-MTHF) is the biologically active form of reduced folate, which can increase BH4 availability. 5-MTHF is available as a nutritional vitamin (Merck \& Cie) for human use including during pregnancy. Two out of three preeclamptic study groups will receive 5-MTHF - one at a low dose and the other at a high dose.
Study NCT05434195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Arcofolin® Placebo
Description: The placebo, this consists of the same excipients as 5-MTHF, microcrystalline cellulose and silica with no active ingredient.
Study NCT04932655 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: simufilam
Description: Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide
Study NCT04871048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) active
Description: Stimulation will be performed using a Neurocan DC-Stimulator Plus with two 7×5 cm sponge electrodes soaked in a saline solution. Electrodes will be placed in accordance with the international 10-20 electrode placement system: the anode over F4 (right DLPFC), the cathode over Fp1 (MPFC). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day (separated by at least 3 hours) for 5 consecutive weekdays.
Study NCT04871048 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) non active
Description: The control group will receive the sham stimulation following the same regimen, using the sham procedure which has been developed by the manufacturer of the tDCS material, allowing sensations to be felt in the scalp which are the equivalent to those of the active stimulation. The same device will be used for both the sham and the active procedures.
Study NCT04943328 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Total Hip Arthroplasty
Description: cemented hip arthroplasty
Study NCT06220461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Infants allocated to the intervention group will receive folic acid (50 mcg flat dose/day) starting at 14 days of age.
Study NCT06529263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: newborn massage
Description: Newborn massage is one of the complementary treatment methods that support the treatment and contribute to the development of the baby
Study NCT05236075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shearing wave collar
Description: Collar inducing shearing wave to treat obstructive sleep disorders
Study NCT05522608 — intervention group
Intervention type: PROCEDURE
Intervention: transabdominal preperitoneal hernia repair
Description: It is made through 3 holes, 10 mm optical port from the umbilicus, and 5 mm ports each from the right and left lower quadrants. The peritoneum is opened a few cm above the defect in the form of an arc. Dissection of the peritoneum, first lateral and then medial to the defect, is performed. It is continued until the pubic bone is found medially and the periphery of the bone is released. The dissection of the cord elements and the sac is completed. Posterior dissection is a very important step to avoid recurrence. Here, the peritoneum is thoroughly dissected posteriorly, the ductus deferens and vessels are removed from the peritoneum so that no recurrence occurs under the patch. 1-2 to the pubic tubercle, 3-5 to the upper edge of the patch, to the upper edge. Staples at the upper edge should remain above the iliopubic tract, no staples should be placed below. The patch is closed by overlapping the peritoneal leaves so that the patch is not visible.
Study NCT04960696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OSDI
Description: Change of OSDI in distance education
Study NCT05005195 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Low dose abdominal computed tomography scan
Description: A policy of invitation to a targeted community-based non-contrast CT screening of the abdomen in those at risk of kidney cancer
Study NCT04960696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: tear break up time
Description: Change of tear break up time in distance education
Study NCT04960696 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: schirmer
Description: Change of schirmer in distance education
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: tyrosine kinase inhibitors
Study NCT05582499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: tyrosine kinase inhibitors
Study NCT06664879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG-453 + Azacitidine
Description: Given intravenously (by vein)
Study NCT06626139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Healthy participants will receive up to 25 mg psilocybin.
Study NCT06626139 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Context 1
Description: Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.
Study NCT06626139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Context 1
Description: Drug administration will take place in a context (Context 1) that is expected to modulate acute and post-acute drug effects.
Study NCT06626139 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Context 2
Description: Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.
Study NCT06626139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Context 2
Description: Drug administration will take place in a context (Context 2) that is expected to modulate acute and post-acute drug effects.
Study NCT06626139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy participants will receive an inactive placebo.
Study NCT06681909 — intervention group
Intervention type: BEHAVIORAL
Intervention: UB Campus Veggie Van
Description: The UB Veggie Van is based on the Veggie Van, an evidence-based mobile produce market intervention. Mobile markets are like farmers' markets on wheels that travel to underserved communities selling high-quality, low-cost produce and healthy foods. The Veggie Van mobile market model was developed through multiple research studies on the efficacy, effectiveness, and implementation of the intervention, and is a multi-level intervention that addresses the five components of nutrition security (availability, accessibility, affordability, stability, and utilization). The UB Veggie Van is operated according to the Veggie Van model, with specific adaptations made to more effectively reach the campus community (Aim 1 of the larger funded study).
Study NCT04908735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Participants will receive ruxolitinib orally twice daily for 24 weeks.
Study NCT04807777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice daily during the entirety of each 28-day cycle.
Study NCT06693986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replicative Adenovirus Vector (RGDCRAdCOX2F)
Description: RGDCRAdcox2F (RGD) is a local product and is provided through this study.
Study NCT06689163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167 tablets
Description: HRS-1167 tablets
Study NCT05646589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care transition support
Description: Person-centred dialogue intended to permeate all patient-provider communication, various pedagogical modes of information, a person-centred care and rehabilitation plan, and a bridging e-meeting to prepare patients for homecoming.for persons who are to be discharged from hospitals after stroke or TIA
Study NCT05646589 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular care transition
Description: Regular care transitions, initiated by an electronic referral from hospital healthcare professionals to the receiving neurorehabilitation team
Study NCT04932733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: The elderly participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
Study NCT04932733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Young isometric exercise
Description: The young participants in the experimental group underwent a single session of 5-minute quadriceps isometric exercise. The participant was asked to take a rest of 10 minutes before performing the exercise. After that, the exercise was performed from a long-sitting position.
Study NCT06689163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate tablets（II）
Description: Abiraterone Acetate tablets（II）
Study NCT05863156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Right side lying position
Description: In the study, 60 participants were placed in the right side lying position (intervention 1)
Study NCT06689163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone Acetate tablets
Description: Prednisone Acetate tablets
Study NCT05863156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semi Fowler
Description: In the study, 60 participants in the semi-sitting position (intervention 2)
Study NCT05863156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: left side lying position
Description: In the study, 120 participants in the left side lying position (control group).
Study NCT04773093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous Intravenous Lidocaine Infusion
Description: Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
Study NCT04773093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will recieve Placebo NaCl 0.9% continuous intravenous infusion until the completion of surgery
Study NCT04780334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 RT-PCR
Description: Nasopharyngeal swabs for COVID-19 RT-PCR
Study NCT04780334 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor
Description: Portable and Connected Biosensor viral
Study NCT06701539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine group
Description: After standardized anesthesia induction, bilateral scalp nerve block (supprorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was performed with liposome bupivacaine stock solution, and 1-2ml was injected into each block site.
Study NCT06701539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine group
Description: After standardized anesthesia induction, bilateral scalp nerve block (supraorbital nerve, auriculotemporal nerve, major occipital nerve, minor occipital nerve) was administered with 0.5% ropivacaine, and 1-2ml was injected into each block site.
Study NCT05582421 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Diclofenac Sodium
Description: intracanal medication
Study NCT05582421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: intracanal medication
Study NCT04808063 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh implantation
Description: Use of an algorithm for prophylactic mesh implantation in high risk patients after emergency midline laparotomy.
Study NCT04687917 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The facilitation, training, feedback, and consultation (FTFC) Strategy
Description: A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, and consultation
Study NCT04687917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The facilitation, training, feedback, consultation, and pay-for-performance (FTFC+PFP) Strategy
Description: A multilevel implementation strategy that includes team-focused facilitation, as well as staff-focused training, feedback, consultation, and pay-for-performance.